Granted Patent
B2
US 12,576,064 · App. 19/311,629 · Granted Mar 17, 2026
Urolithin gummy (pectin) formulations
Inventors:
Christopher L. Rinsch (Lausanne, CH); Anurag Singh (Lausanne, CH); William Blanco-Bose (La Croix, CH); Davide D'Amico (Renens, CH); Alan McClure (Columbia, MO)
Assignee:
Amazentis SA
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The invention relates to composition of urolithins comprising urolithins and pectin and formulations of urolithins, specifically chewable formulations, comprising urolithins and a gelling agent. The invention further comprises compositions and chewable formulations comprising urolithins in combination with other active ingredients and processes for the preparation of such compositions and formulations. The invention further comprises methods of using such compositions and formulations in the treatment of conditions and diseases and for the promotion of health and performance, such in the improving muscle function.
Claims (30)
1 . A composition comprising urolithin A or a salt thereof; and pectin; wherein the ratio of urolithin A to pectin is about 1:2 (w/w) to about 10:1 (w/w).
2 . The composition of claim 1 , wherein the pectin is selected from low methoxyl pectin, high methoxyl pectin, and amidated low methoxyl pectin, or a mixture of any of them.
3 . The composition of claim 2 , wherein the pectin is an amidated low methoxyl pectin.
4 . The composition of claim 1 , wherein the amount of urolithin A or salt thereof is about 1% to about 20% (w/w).
5 . The composition of claim 4 , wherein the amount of urolithin A or salt thereof is about 5% to about 15% (w/w).
6 . The composition of claim 4 , wherein the amount of urolithin A or salt thereof is about 5% to about 10% (w/w).
7 . The composition of claim 1 , wherein the amount of pectin is about 0.5% to about 4% (w/w).
8 . The composition of claim 7 , wherein the amount of pectin is about 0.5% to about 3% (w/w).
9 . The composition of claim 1 , further comprising one or more low-calorie sweeteners.
10 . The composition of claim 9 , wherein the one or more low-calorie sweeteners is selected from stevia and fructooligosaccharide.
11 . The composition of claim 1 , further comprising soluble fibre.
12 . The composition of claim 11 , wherein the soluble fibre is soluble tapioca fibre or inulin-derived fibre.
13 . The composition of claim 1 , further comprising a citrate salt.
14 . The composition of claim 13 , wherein the citrate salt is sodium citrate.
15 . The composition of claim 1 , further comprising one or more low-calorie sweeteners; soluble fibre; and a citrate salt.
16 . The composition of claim 15 , wherein the amount of urolithin A or salt thereof is about 1% to about 20% (w/w).
17 . The composition of claim 16 , wherein the amount of pectin is about 0.5% to about 4% (w/w).
18 . The composition of claim 17 , wherein the amount of one or more low-calorie sweeteners is about 25% to about 45% (w/w); the amount of soluble fibre is about 25% to about 45% (w/w); and the amount of citrate salt is about 0.1% to about 2% (w/w).
19 . The composition of claim 18 , wherein the pectin is selected from low methoxyl pectin, high methoxyl pectin, and amidated low methoxyl pectin, or a mixture of any of them.
20 . The composition of claim 19 , wherein the pectin is amidated low methoxyl pectin extracted from citrus peel.
21 . The composition of claim 18 , wherein the soluble fibre is soluble tapioca fibre.
22 . The composition of claim 18 , wherein the one or more low-calorie sweeteners is selected from stevia and fructooligosaccharide.
23 . The composition of claim 18 , wherein the citrate salt is sodium citrate.
24 . The composition of claim 1 , wherein the composition is in the form of a gummy.
25 . The composition of claim 1 , wherein the amount of urolithin A or salt thereof is about 100 mg to about 2500 mg.
26 . The composition of claim 1 , wherein the amount of urolithin A or salt thereof is about 1000 mg.
27 . The composition of claim 1 , wherein the amount of urolithin A or salt thereof is about 500 mg.
28 . The composition of claim 1 , wherein the amount of urolithin A or salt thereof is about 250 mg.
29 . The composition of claim 1 , wherein the amount of urolithin A or salt thereof is about 5% to about 20% (w/w); and the amount of pectin is about 0.5% to about 5% (w/w).
30 . The composition of claim 10 , comprising stevia in amount of about 0.001% to about 3% (w/w).
Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Feb 5, 2026
From: RINSCH, CHRISTOPHER L.; SINGH, ANURAG; BLANCO-BOSE, WILLIAM; D'AMICO, DAVIDE
To: AMAZENTIS SA
Reel/Frame 074721/0780 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Feb 5, 2026
From: PATRIC CHOCOLATE, LLC
To: AMAZENTIS SA
Reel/Frame 073704/0940 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Feb 5, 2026
From: MCCLURE, ALAN
To: PATRIC CHOCOLATE, LLC
Reel/Frame 073704/0877 →
Priority Claims (1)
GB 2308224
· Jun 1, 2023
· national
Continuity (2)
References Cited (319)
US 5073545A
· Arima et al.
· 1991
[cited by applicant]
US 5411757A
· Buist et al.
· 1995
[cited by applicant]
US 6066312A
· Egawa et al.
· 2000
[cited by applicant]
US 6133311A
· Bok et al.
· 2000
[cited by applicant]
US 6440436B1
· Ghosal
· 2002
[cited by applicant]
US 8183282B2
· Seeram et al.
· 2012
[cited by applicant]
US 8894993B2
· Ghosal
· 2014
[cited by applicant]
US 8933217B2
· Rinsch et al.
· 2015
[cited by applicant]
US 9394269B2
· Rinsch et al.
· 2016
[cited by applicant]
US 9573922B2
· Rinsch et al.
· 2017
[cited by applicant]
US 9872850B2
· Rinsch et al.
· 2018
[cited by applicant]
US 9962366B2
· Rinsch et al.
· 2018
[cited by applicant]
US 9980980B2
· Rinsch et al.
· 2018
[cited by applicant]
US 9994542B2
· Rinsch et al.
· 2018
[cited by applicant]
US 20030078212A1
· Li et al.
· 2003
[cited by applicant]
US 20050282781A1
· Ghosal
· 2005
[cited by applicant]
US 20060257337A1
· Sherris
· 2006
[cited by applicant]
US 20070148292A1
· Royo
· 2007
[cited by examiner]
US 20080039179A1
· Seelig et al.
· 2008
[cited by applicant]
US 20080214656A1
· Lim et al.
· 2008
[cited by applicant]
US 20100004334A1
· Jouni et al.
· 2010
[cited by applicant]
US 20100055247A1
· Tirrito
· 2010
[cited by applicant]
US 20110263521A1
· Moutet et al.
· 2011
[cited by applicant]
US 20150104539A1
· Daniels
· 2015
[cited by examiner]
US 20160095881A1
· Sen
· 2016
[cited by applicant]
US 20180015069A1
· Rinsch et al.
· 2018
[cited by applicant]
US 20180256471A1
· Rinsch et al.
· 2018
[cited by applicant]
US 20180256538A1
· Rinsch et al.
· 2018
[cited by applicant]
US 20180296464A1
· Graban et al.
· 2018
[cited by applicant]
US 20190000867A1
· Rinsch et al.
· 2019
[cited by applicant]
US 20200085895A1
· Patel et al.
· 2020
[cited by applicant]
US 20210210190A1
· Rinsch et al.
· 2021
[cited by applicant]
US 20210251869A1
· Rinsch et al.
· 2021
[cited by applicant]
US 20210346342A1
· Rinsch et al.
· 2021
[cited by applicant]
US 20210369805A1
· Wan et al.
· 2021
[cited by applicant]
US 20220280410A1
· Perretta et al.
· 2022
[cited by applicant]
US 20230277669A1
· Rinsch et al.
· 2023
[cited by applicant]
US 20230301890A1
· Rinsch et al.
· 2023
[cited by applicant]
US 20230355501A1
· Ookura et al.
· 2023
[cited by applicant]
US 20230390238A1
· Rinsch et al.
· 2023
[cited by applicant]
US 20240148690A1
· Andreux et al.
· 2024
[cited by applicant]
US 20240156777A1
· Rinsch et al.
· 2024
[cited by applicant]
US 20240366558A1
· Rinsch et al.
· 2024
[cited by applicant]
US 20250049750A1
· Rinsch et al.
· 2025
[cited by applicant]
US 20250161391A1
· Rinsch et al.
· 2025
[cited by applicant]
US 20250213524A1
· Rinsch et al.
· 2025
[cited by applicant]
US 20250228817A1
· Rinsch et al.
· 2025
[cited by applicant]
CN 101301319A
· 2008
[cited by applicant]
CN 101484125A
· 2009
[cited by applicant]
CN 101541182A
· 2009
[cited by applicant]
CN 103442594A
· 2013
[cited by applicant]
CN 109316478A
· 2019
[cited by applicant]
CN 110368476A
· 2019
[cited by applicant]
CN 112843049A
· 2021
[cited by applicant]
CN 113171319A
· 2021
[cited by applicant]
CN 113476362A
· 2021
[cited by applicant]
CN 113855758A
· 2021
[cited by applicant]
CN 114794490A
· 2022
[cited by applicant]
CN 115868614A
· 2023
[cited by applicant]
CN 115887392A
· 2023
[cited by applicant]
CN 116889583A
· 2023
[cited by applicant]
EP 2033526A1
· 2009
[cited by applicant]
EP 2068864A2
· 2009
[cited by applicant]
EP 2654461A2
· 2013
[cited by applicant]
EP 3278800A2
· 2018
[cited by applicant]
JP H02304080A
· 1990
[cited by applicant]
JP 2008503456A
· 2008
[cited by applicant]
JP 2010280627A
· 2010
[cited by applicant]
JP 2016216378A
· 2016
[cited by applicant]
JP 2017007951A
· 2017
[cited by applicant]
JP 2017014154A
· 2017
[cited by applicant]
JP 2017019725A
· 2017
[cited by applicant]
JP 6054301B2
· 2017
[cited by applicant]
JP 2017031108A
· 2017
[cited by applicant]
JP 2022185501A
· 2022
[cited by applicant]
WO WO0006134A2
· 2000
[cited by applicant]
WO WO0015044A1
· 2000
[cited by applicant]
WO WO0149281A2
· 2001
[cited by applicant]
WO WO02094984A2
· 2002
[cited by applicant]
WO WO2003013438A2
· 2003
[cited by applicant]
WO WO2005077899A2
· 2005
[cited by applicant]
WO WO2005097106A1
· 2005
[cited by applicant]
WO WO2006007310A2
· 2006
[cited by applicant]
WO WO2006127832A2
· 2006
[cited by applicant]
WO WO2007101247A2
· 2007
[cited by applicant]
WO WO2007127263A2
· 2007
[cited by applicant]
WO WO2008016554A1
· 2008
[cited by applicant]
WO WO2007133249A3
· 2009
[cited by applicant]
WO WO2009031023A2
· 2009
[cited by applicant]
WO WO2009120799A2
· 2009
[cited by applicant]
WO WO2009153652A2
· 2009
[cited by applicant]
WO WO2011011721A2
· 2011
[cited by applicant]
WO WO2012088519A2
· 2012
[cited by applicant]
WO WO2012103487A1
· 2012
[cited by applicant]
WO WO2012113835A1
· 2012
[cited by applicant]
WO WO2012156600A1
· 2012
[cited by applicant]
WO WO2014004902A2
· 2014
[cited by applicant]
WO WO2015100213A2
· 2015
[cited by applicant]
WO WO2017109195A1
· 2017
[cited by applicant]
WO WO2018162650A1
· 2018
[cited by applicant]
WO WO2018162651A1
· 2018
[cited by applicant]
WO WO2019168972A1
· 2019
[cited by applicant]
WO WO2021237214A1
· 2021
[cited by applicant]
WO WO2022063846A1
· 2022
[cited by applicant]
WO WO2023031673A1
· 2023
[cited by applicant]
WO WO2023237926A2
· 2023
[cited by applicant]
WO WO2024246601A1
· 2024
[cited by applicant]
WO WO2024246603A1
· 2024
[cited by applicant]
WO WO2025078619A1
· 2025
[cited by applicant]
WO WO2025078645A1
· 2025
[cited by applicant]
Mitopure Gummies, accessed online Oct. 6, 2025 (Year: 2025).
[cited by examiner]
Singh et al. (Direct Supplementation with Urolithin A overcomes limitations of dietary exposure and gut microbiome variability in healthy adults to achieve consistent levels across the population, European Journal of Cl…
[cited by examiner]
“Questions and Answers on Dietary Supplements.” FDA, 2024. https://www.fda.gov/food/information-consumers-using-dietary-supplements/questions-and-answers-dietary-supplements.
[cited by applicant]
Abstract of unexamined Japanese application No. JP2010-280627 published Dec. 16, 2010.
[cited by applicant]
Adams et al., “Pomegranate Ellagitannin-Derived Compounds Exhibit Antiproliferative and Antiaromatase Activity in Breast Cancer Cells In Vitro,” Cancer Prev Res, 3: 108-113 (2010).
[cited by applicant]
Andreux et al., “Appendix A: The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans,” Nature Metabolish, 1:595-603 (2019).
[cited by applicant]
Andreux et al., “The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans,” Nature Metabolism, 1:595-603 (2019).
[cited by applicant]
Bai et al., “Active Compounds from Lagerstroemia speciosa, Insulin-like Glucose Uptake-Stimulatory/Inhibitory and Adipocyte Differentiation-Inhibitory Activities in 3T3-L1 Cells,” J Agric Food Chem, 56(24):11668-11674 (…
[cited by applicant]
Basu et al., “Pomegranate juice: A heart-healthy fruit juice,” Nutr Rev, 67(1): 49-56 (2009).
[cited by applicant]
Berry Health Benefits Symposium (2009 Berry Health Benefis Symposium).
[cited by applicant]
Bhattacharyya et al., “Beneficial Effect of Processed Shilajit on Swimming Exercise Induced Impaired Energy Status of Mice,” Pharmacologyonline, 1: 817-825 (2009).
[cited by applicant]
Bhattacharyya et al., “Shilajit Dibezno-alpha-Pyrones: Mitochondria Targeted Antioxidants,” Pharmacologyonline, 2: 690-698 (2009).
[cited by applicant]
Bialonska, et al., “Urolithins, Intenstinal Microbial Metabolites of Pomegranate Ellagitannins, Exhibit Potent Antioxidant Activity in a Cell-Based Assay,” J Agric Food Chem, 57(21); 10181-10186, 2009.
[cited by applicant]
Bishayee, “Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials.” Cancer Prevention Research 2(5) (2009): 409-418.
[cited by applicant]
Bishop et al., “Neural mechanisms of ageing and cognitive decline,” Nature, 464(7288):529-535 (2010).
[cited by applicant]
Brummer et al., “Particle Characterisation in Excipients, Drug Products and Drug Substances” SGS Life Science Services, Issue 11: 6 pages (2008).
[cited by applicant]
Cerda et al., “Identification of Urolithin A as a metabolite produced by human colon microflora from ellagic acid and related compounds,” J Agric Food Chem, 53(14): 5571-5576 (2005).
[cited by applicant]
Cerda et al., “Pomegranate juice supplementation in a chronic obstructive pulmonary disease: a 5-week, randomized, double-blind, placebo-controlled trial,” Eur J Clin Nutr, 60: 245-253 (2006).
[cited by applicant]
Cerda et al., “Repeated oral administration of high doses of the pomegranate ellagitannin punialagin to rats for 37 days is not toxic,” J. Agric. Food Chem., 51(11):3493-3501 (2003).
[cited by applicant]
Chaudhary et al., “Enhancement of solubilization and bioavailability of poorly soluble drugs by physical and chemical modifications: A recent review,” Journal of Advanced Pharmacy Education & Research, 2(1):32-67 (2012).
[cited by applicant]
Chen et al., “Coordination of Autophagy and the Proteasome in Resolving Endoplasmic Reticulum Stress,” Veterinary Pathology 48(1):245-253 (2011).
[cited by applicant]
Chen et al., “Resveratrol ameliorates metabolic disorders and muscle wasting in streptozotocin-induced diabetic rats,” American Journal of Physiology Endocrinology and Metabolism 301.5 (2011): E853-E863.
[cited by applicant]
Chen, T. et al., “Rapamycin and other longevity-promoting compounds enhance the generation of mouse induced pluripotent stem cells”, Aging Cell, 10(5):908-911 (Anatomical Society of Great Britain and Ireland, UK, Jun. 1…
[cited by applicant]
Cintamani, “Dadima (anara) Guna” Gangavishnu Shrikrishan Das, 170 (1937).
[cited by applicant]
Curto et al., “Inhibitors of mammalian melanocyte tyrosinase: in vitro comparisons of alkyl esters of gentisic acid with other putative inhibitors,” Biochem Pharmacol, 57:663-672 (1999).
[cited by applicant]
De Meyer et al., “Autophagy in the cardiovascular system,” Biochimica et Biophysica Acta 1793: pp. 1485-1495 (2009).
[cited by applicant]
Dell'agli, et al., “Ellagitannins of fruit rind of pomegranate (
[cited by applicant]
Du et al., “Starving Neurons Show Sex Difference in Autophagy,” The Journal of Biological Chemistry, 284(4): 2383-2396 (2009).
[cited by applicant]
Eisenberg et al., “Induction of autophagy by spermidine promotes longevity.” Nature Cell Biology 11(11) (2009): 1305-1314.
[cited by applicant]
Ertam et al., “Efficiency of ellagic acid and arbutin in melasma: A randomized, prospective, open-label study,” Journal of Dermatology, 35: 570-574 (2008).
[cited by applicant]
Esmaillzadeh et al., “Concentrated pomegranate juice improves lipid profiles in diabetic patients with hyperlipidemia,” J Med Food, 7(3): 305-308 (2004).
[cited by applicant]
Espin et al., “Iberian pig as a model to clarify obscure points in the bioavailability and metabolism of ellagitannins in humans,” J Agric Food Chem, 55(25): 10476-10485 (2007).
[cited by applicant]
Extended European Search Report for EP Application No. 18166896.3 dated Jun. 6, 2018.
[cited by applicant]
Extended European Search Report for EP Application No. 18166897.1 dated May 28, 2018.
[cited by applicant]
Extended European Search Report for EP Application No. 23175506.7 dated Jan. 8, 2023.
[cited by applicant]
Farris, “The anti-aging effects of niacinamide” Dermatology Times, [online] Oct. 14, 2015<https://www.dermatologytimes.com/view/anti-aging-effects-niacinamide>.
[cited by applicant]
Friedman et al., “NSAIDs in Dermatologic Therapy: Review and Preview.” J Cutan Med Surg 2002, 6(5):449-59.
[cited by applicant]
Ghosal et al., “Effects of shilajit and its active constituents on learning and memory in rats,” Phytotherapy Res, 7(1): 29-34 (1993).
[cited by applicant]
Ghosal et al., “Shilajit. Part 4. Chemistry of Two Bioactive Benzopyrone Metabolites,” J Chem Research (S), 11: 350-351 (1989).
[cited by applicant]
Gimenez-Bastida et al., “Ellagitannin metabolites, urolithin A glucuronide and its aglycone urolithin A, ameliorate TNF-induced inflammation and associated molecular markers in human aortic endothelial cells,” Mol. Nutr…
[cited by applicant]
Gonzalez-Sarrias et al., “Dissimilar In Vitro and In Vivo Effects of Ellagic Acid and Its Microbiota-Derived Metabolites, Urolithins, on the Cytochrome P450 1A1,” Journal of Agricultural and Food Chemistry, 57: 5623-563…
[cited by applicant]
Gonzalez-Sarrias et al., “NF-? B-dependent anti-inflammatory activity of urolithins, gut microbiota ellagic acid-derived metabolites, in human colonic fibroblasts.” British Journal of Nutrition 2010, 104, 503-512.
[cited by applicant]
Gulcin et al., “Antioxidant and Antiradical Activities of L-carnitine,” Life Sciences, 78: 803-811 (2006).
[cited by applicant]
Hartman et al., “Pomegranate juice decreases amyloid load and improves behavior in a mouse model of Alzheimer's disease”, Neurobiology of Disease, 24(3):506-515 (Elsevier Inc., St. Louis, MO 2006).
[cited by applicant]
Hipkiss, “Aging, proteotoxicity, mitochondria, glycation, NAD+ and carnosine: possible inter-relationships and resolution of the oxygen paradox”, Frontiers in aging neuroscience: 10 (2010).
[cited by applicant]
Hoefer et al., “Fear conditioning in frontotemporal lobar degeneration and Alzheimer's disease,” Brain, 131: 1646-1657 (2008).
[cited by applicant]
Hu et al., “Efficacy and comparative effectiveness of sirolimus as an anticancer drug.” The Laryngoscope 121(5) (2011): 978-982.
[cited by applicant]
Ibn-e-Sina, “Halelah” Institute of History of Medicine and Medical Research, 409-410 (1987).
[cited by applicant]
IN Application No. 392/CHE/2004 A (DSM IP Assets BV [NL]), filed Apr. 28, 2004.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/EP24/80149 dated Jan. 29, 2025.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US11/67229 dated Jul. 25, 2024.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US13/48310 dated Jan. 22, 2014.
[cited by applicant]
Ishimoto H. et al., “In vivo anti-inflammatory and antioxidant properties of ellagitannin metabolite urolithin A.” Bioorg Med Chem Lett, 21(19): 5901-5904 (2011).
[cited by applicant]
Islam et al. “Biotransformation of 3-hydroxydibenzo-a-pyrone into 3, 8 dihydroxydibenzo-a-pyrone and aminoacyl conjugates by Aspergillus niger isolated from native “shilajit”.” Electronic Journal of Biotechnology 11.3 (…
[cited by applicant]
Johanningsmeier et al., “Pomegranate as a functional food and nutraceutical source,” Ann Rev Food Sci Technol, 2:181-201 (2010).
[cited by applicant]
Kaarniranta et al., “Age-Related Macular Degeneration (AMD): Alzheimer's Diesease in the Eye?,” Journal of Alzheimer's Disease, 24(4):615-631 (2011).
[cited by applicant]
Kabiruddin, “Rubb-e- Anaar Sheerin” Daftar-al-Maseeh, 75 (1938).
[cited by applicant]
Kasimsetty, et al., “Colon cancer chemopreventive activities of pomegranate ellagitannins and Urolithins,” J Agric Food Chem, 58(4): 2180-2187 (2010).
[cited by applicant]
Kharkevich, “Parmakolociva” [Pharmacology], Manual for Students of Medical Institutes, Moscow, Meditsina, 47-48 (1987).
[cited by applicant]
Kiss et al., “Epigenetic modulation of mechanisms involved in inflammation: Influence of selected polyphenolic substances on histone acetylation state”, Food Chemistry, 131(3):1015-1020 (Elsevier Ltd., Netherlands, Sep.…
[cited by applicant]
Landete, “Ellagitannins, ellagic acid and their derived metabolites: A review about source, metabolism, functions and health”, Food Research International, 44(5):1150-1160 (Elsevier Applied Science, Barking, GB, Apr. 17…
[cited by applicant]
Larrosa et al., “Anti-inflammatory properties of a pomegranate extract and its metabolite urolithin-A in a colitis rat model and the effect of colon inflammation on phenolic metabolism”, Journal of Nutritional Biochemis…
[cited by applicant]
Larrosa et al., “Ellagitannins, ellagic acid and vascular health”, Molecular Aspects of Medicine, 31(6):513-539 (Pergamon Press, Oxford, Great Britain, Dec. 1, 2010).
[cited by applicant]
Lee et al., “b-Secretase (BACE1) Inhibitors from Sanguisorbae Radix”, Arch. Pharm. Res., 28(7):799-803 (Korea, 2005).
[cited by applicant]
Lin et al., “Pharmacological Promotion of Autophagy Alleviates Steatosis and Injury in Alcoholic and Non-alcoholic Fatty Liver Conditions in Mice,” J Hepatol. May 2013; 58(5):993-999.
[cited by applicant]
Liu et al. “Antiaging effects of urolithin A on replicative senescent human skin fibroblasts”, Rejuvenation Research, 22(3): 191-200 (2019).
[cited by applicant]
Liu et al., “Appendix C: Impact of Urolithin A vs Placebo Supplementation on Muscle Endurance and Mitochondrial Health in the Elderly: A Randomized Clinical Trial,” Manuscript Draft.
[cited by applicant]
Liu et al., “Chemical constituents of Panax ginseng and Panax notoginseng explain why they differ in therapeutic efficacy.” Pharmacological Research 161 (2020): 105263.
[cited by applicant]
Majoosi, “Rubb-e-Rumman” Central Council for Research in Unani Medicine, 591 (2005).
[cited by applicant]
Manach et al., “Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies 1-3,” Am. J. Clin. Nutr. 81(suppl):230S-242S (2005).
[cited by applicant]
Markaki et al., “Modeling human diseases in Caenorhabditis elegans,” Biotechnol J, 5:1261-1276 (2010).
[cited by applicant]
Mingorance et al., “Critical update for the clinical use of L-carnitine analogs in cardiometabolic disorders,” Vascular Health and Risk Management, 7:169-176 (2011).
[cited by applicant]
National Institute of Mental Health, “I'm So Stressed Out!” Fact Sheet, 2023, retrieved from https://www.nimh.nih.gov/sites/default/files/documents/health/publications/so-stressed-out-fact-sheet/Im-So-Stressed-Out.pdf, …
[cited by applicant]
Ndiaye et al., “The grape antioxidant resveratrol for skin disorders: promise, prospects, and challenges.” Arch Biochem Biophys 2011, 508(2) 164-170.
[cited by applicant]
Nih, “What Is Atherosclerosis?” NHLBI, National Institutes of Health (2016).
[cited by applicant]
Nolan et al., “Over-the-Counter Topical Skincare Products: A Review of the Literature.” Journal of Drugs in Dermatology, 2012, 11(2), 220-224.
[cited by applicant]
Pandya et al., “Disorders of Hyperpigmentation,” New and Emerging Therapies, 18(1):91-98 (2000).
[cited by applicant]
Park et al., “Micronization of arbutine using supercritical anti-solvent,” Korean Journal of Chemical Engineering, 25(3): 581-584 (2008).
[cited by applicant]
Partial European Search Report for European Application No. 17186188.3 dated Oct. 27, 2017.
[cited by applicant]
Paula's choice skincare, “Trehalose”, [online] https://www.paulaschoice.com/ingredients/ingredient-trehalose.html [Accessed Aug. 11, 2022].
[cited by applicant]
Percival, “Antioxidants,” Clinical Nurtition Insights, 1998.
[cited by applicant]
Puzzo et al., “Behavioral assays with mouse models of Alzheimer's disease: practical considerations and guidelines,” Biochemical Pharmacology, 88(4): 46 pages (2014).
[cited by applicant]
Ratnam et al., “The co-encapsulated antioxidant nanoparticles of ellagic acid and coenzyme Q10 ameliorates hyperlipidemia in high fat diet fed rats,” Journal of Nanoscience and Nanotechnology 9 (2009): 6741-6746.
[cited by applicant]
Raza et al., “Effect of Bitter Melon (
[cited by applicant]
Raza et al., “Modulation of Xenobiotic Metabolism and Oxidative Stress in Chronic Streptozotocin-Induced Diabetic Rats Fed with Momordica charantia Fruit Extract,” J Biochem Molecular Toxicology, 14(3): 131-139 (2000).
[cited by applicant]
Reuter et al., “Carnitine and Acylcarnitines Pharmacokinetic, Pharmacological and Clinical Aspects,” Clin Pharmacokinet, 51 (9): 553-572 (2012).
[cited by applicant]
Rock et al., “Consumption of wonderful variety pomegranate juice and extract by diabetic patients increases paraoxonase 1 association with high-density lipoprotein and stimulates its catalytic activities,” J Agric Food …
[cited by applicant]
Rubinsztein et al., “Autophagy and aging”, Cell 146(5): 682-695 (2011).
[cited by applicant]
Ryu et al., “Urolithin A induces mitophagy and prolongs lifespan in C. elegans and increases muscle function in rodents” Nature Medicine, vol. 22, No. 8 (2016).
[cited by applicant]
Sanders et al., “The place of the hippocampus in fear conditioning,” European Journal of Pharmacology, 463: 217-223 (2003).
[cited by applicant]
Sarasamgrahah, “Anara Sarbata” Shri Baidyanath Ayurveda Bhavan Limited, 569 (2003).
[cited by applicant]
Sastre et al., “The role of mitochondrial oxidative stress in aging”, 2003, Free Radio Biol Med, 35: 1-8.
[cited by applicant]
Saul et al., “Diversity of Polyphenol Action in Caenohabditis elegans: Between Toxicity and Longevity”, Journal of Natural Products, 74(8):1713-1720 (American Chemical Society and American Society of Pharmacognosy, USA,…
[cited by applicant]
Search Report for GB Application No. 2308224, dated Nov. 27, 2023.
[cited by applicant]
Search Report for GB Application No. 2316295.1 dated Apr. 18, 2024.
[cited by applicant]
Seeram et al., “Pomegranate Ellagitannin-Derived Metabolites Inhibit Prostate Cancer Growth and Localize to the Mouse Prostate Gland”, J. Agric. Food Chem., 55:7732-7737 (American Chemcal Society, USA, 2007).
[cited by applicant]
Silverman et al., “Modeling molecular and cellular aspects of human disease using the nematode caenorhabditis elegans,” Pediatric Research, 65(1):10-18 (2009).
[cited by applicant]
Singh et al., “Appendix B: Urolithin A improves leg muscle strength, exercise performance and mitochondrial health in a proof-of-concept clinical trial in overweight adults,” Manuscript Draft.
[cited by applicant]
Song et al., “Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells.” Scientific Reports 2 (2012): 362.
[cited by applicant]
Sorgen, “Eat Smart for a Healthier Brain,” WebMD, accessed online:https://www.webmd.com/diet/features/eat-smart-healthier-brain?print=true.
[cited by applicant]
Stout et al., “Mitochondria's Role in Skin Ageing,” Biology, 8(29): 12 pages (2019).
[cited by applicant]
Sumner et al., “Effects of pomegranate juice consumption on myocardial perfusion in patients with coronary heart disease,” Am J Cardiol, 96(6): 810-814 (2005).
[cited by applicant]
Taylor et al., “Behavioral phenotyping of mouse models of Parkinson's Disease,” Behavioural Brain Research, 211(1): 19 pages (2010).
[cited by applicant]
Third Party Observation for Application No. EP20180166897, dated Apr. 8, 2024.
[cited by applicant]
Trombold et al., “Ellagitannin Consumption Improves Strength Recovery 2-3 d after Eccentric Exercise”, Medicine and Science in Sports and Exercise, 42:493-498 (American College of Sports Medicine, Mar. 2010).
[cited by applicant]
Uchida, “Pathologic Changes and Autophagy: New Insights for the Pathogenesis of Animal Diseases,” Veterinary Pathology 54(6):881-884 (2017).
[cited by applicant]
Verzelloni et al., “Antiglycative and Neuroprotective Activity of Colon-Derived Polyphenol Catabolites” Molecular Nutrition and Food Research, 55(1): S35-S43 (2011).
[cited by applicant]
Verzelloni et al., “Antiglycative and neuroprotective activity of colonderived polyphenol catabolites.” Mol. Nutr. Food Res, 55(1):35-43 (2011).
[cited by applicant]
Viuda-Martos et al., “Pomegranate and its Many Functional Components as Related to Human Health: A Review”, Comprehensive Reviews in Food Science and Food Safety, 9(6):635-654 (Oct. 22, 2010).
[cited by applicant]
Wang et al., “Antimelanogenic Effect of Urolithin A and Urolithin B, the Colonie Metabolites of Ellagic Acid, in B16 Melanoma Cells” Journal of Agricultural and Food Chemistry, 65: 6870-6876 (2017).
[cited by applicant]
Wang et al., “Gut microbial transformation, a potential improving factor in the therapeutic activities of four groups of natural compounds isolated from herbal medicines.” Fitoterapia 138 (2019): 104293.
[cited by applicant]
Zenjun et al., “Distribution of Ellagic Acids in Plantae and Thier Bioactivies,” Natural Product Research and Development, 22:519-524 and 540 (2010).
[cited by applicant]
Zihong, “Practical Family Nutrition,” Wuhan University Press, p. 251 (2021).
[cited by applicant]